e11623 Background: TNBC makes about 12.5% of all breast cancer. TNBC show have a poor prognosis due to the aggressive biology with relative resistance to systemic therapies. 85% of TNBC are basal-like subtype. Basal-like TNBC are diagnosed by a positive CK5/14 stainig in immunohistochemical staining. Methods: 200 pts with TNBC in Bayreuth hospital were analysed retrospectively between 1995 and 2006. 52/200 (26%) pts underwent primary systemic therapy (PST). 6/200 pts primary had stage IV disease. In 49 pts ck 5/14 staining was done. Results: The median follow up 56 mts, median age at diagnosis was 52 yrs. At the time of analysis 146/200 pts were alive. DFS was 25 mts, OS 44 mts. 7/42 (16. 6%) had a pathological complete response rate (pCR) after PST, in 5/7 pts PST was based on anthracyclines. The estimated residual tumor size in preoperative MR correlated strongly with the histopathological tumor size (Pearson Correlation r=0,81, p< 0.01). Stage IV patients with viszeral disease had a median age of 69 yrs and median OS 6,3 (2–12 mts). Overall recurrence rate was 24% (48/200 pts). Grading in all TNBC variated (G1: 7 pts (3,5%), G2: 52 pts (26%), G3: 132 pts (66%). Conclusions: The retrospective data demonstrate that basal-like TNBC is an important subgroup with a poor prognosis. In future it will be important to pick up these subgroup to bring them to different therapies. Preoperative MR is a good tool to predict the residual tumor size after PST in all TNBC pts. Anthracycline-based systemic therapy is still standard in adjuvant treatment. No significant financial relationships to disclose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.